Analyzing Perspective Therapeutics (NYSE:CATX) and Beyond Air (NASDAQ:XAIR)

Perspective Therapeutics (NYSE:CATX) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Profitability

This table compares Perspective Therapeutics and Beyond Air’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
Beyond Air	-2,369.17%	-227.29%	-106.51%

Risk and Volatility

Perspective Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500.

Insider and Institutional Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by insiders. Comparatively, 20.1% of Beyond Air shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Perspective Therapeutics and Beyond Air”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	$1.43 million	162.12	-$46.51 million	N/A	N/A
Beyond Air	$1.16 million	25.98	-$60.24 million	($1.41)	-0.30

Perspective Therapeutics has higher revenue and earnings than Beyond Air.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Perspective Therapeutics and Beyond Air, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	1	8	0	2.89
Beyond Air	0	1	3	1	3.00

Perspective Therapeutics currently has a consensus target price of $15.14, indicating a potential upside of 341.48%. Beyond Air has a consensus target price of $3.67, indicating a potential upside of 778.24%. Given Beyond Air’s stronger consensus rating and higher possible upside, analysts plainly believe Beyond Air is more favorable than Perspective Therapeutics.

Summary

Perspective Therapeutics beats Beyond Air on 8 of the 13 factors compared between the two stocks.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.